To selectively enrich gastric cancer PDOs from normal-like PDOs, Nanki K, et al. employed a selection strategy targeting dysregulated signals in human gastric cancer orderly, including (1) nutlin-3 as a marker to specifically enrich TP53-mutant tumors; (2) ROCK inhibitor free culture medium for RHO-dysregulated tumors; (3) TGFβ without A83-01 for TGFβ-insensitive tumors; and (4) EGF and FGF10 free culture media for tumors with constitutive growth receptor pathway activation. This evidence concerns the gene RHO and gastric cancer.